{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:23:07Z","timestamp":1789698187916,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13311-021-01136-0","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:15:52Z","timestamp":1634606152000},"page":"2351-2367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Luuk","family":"Wieske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01136-0_bib1","doi-asserted-by":"crossref","unstructured":"Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology [Internet]. 2016;87:1892\u20138. Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000003293","DOI":"10.1212\/WNL.0000000000003293"},{"key":"10.1007\/s13311-021-01136-0_bib2","doi-asserted-by":"crossref","unstructured":"Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol [Internet]. 2016;31:5\u201320. Available from: http:\/\/link.springer.com\/10.1007\/s10654-015-0094-6","DOI":"10.1007\/s10654-015-0094-6"},{"key":"10.1007\/s13311-021-01136-0_bib3","doi-asserted-by":"crossref","unstructured":"Telleman JA, Herraets IJT, Goedee HS, van Eijk RPA, Verhamme C, Eftimov F, et al. Prognostic value of nerve ultrasound: a prospective multicenter study on the natural history of chronic inflammatory neuropathies. Eur J Neurol [Internet]. 2021;ene.14885. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.14885","DOI":"10.1111\/ene.14885"},{"key":"10.1007\/s13311-021-01136-0_bib4","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools)."},{"key":"10.1007\/s13311-021-01136-0_bib5","doi-asserted-by":"crossref","unstructured":"Siems SB, Jahn O, Eichel MA, Kannaiyan N, Wu LMN, Sherman DL, et al. Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. Elife [Internet]. 2020;9. Available from: https:\/\/elifesciences.org\/articles\/51406","DOI":"10.7554\/eLife.51406"},{"key":"10.1007\/s13311-021-01136-0_bib6","doi-asserted-by":"crossref","unstructured":"Capodivento G, De Michelis C, Carpo M, Fancellu R, Schirinzi E, Severi D, et al. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. J Neurol Neurosurg Psychiatry [Internet]. 2021;92:303\u201310. Available from: https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-324445","DOI":"10.1136\/jnnp-2020-324445"},{"key":"10.1007\/s13311-021-01136-0_bib7","doi-asserted-by":"crossref","unstructured":"Capodivento G, Visigalli D, Garnero M, Fancellu R, Ferrara MD, Basit A, et al. Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies. Sci Rep [Internet]. Springer US; 2017;7:7831. Available from: http:\/\/dx.doi.org\/10.1038\/s41598-017-08314-1","DOI":"10.1038\/s41598-017-08314-1"},{"key":"10.1007\/s13311-021-01136-0_bib8","doi-asserted-by":"crossref","unstructured":"Niezgoda A, Michalak S, Losy J, Kalinowska-\u0141yszczarz A, Kozubski W. sNCAM as a specific marker of peripheral demyelination. Immunol Lett [Internet]. 2017;185:93\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247816302206","DOI":"10.1016\/j.imlet.2017.03.011"},{"key":"10.1007\/s13311-021-01136-0_bib9","doi-asserted-by":"crossref","unstructured":"Kim YH, Kim YH, Shin YK, Jo YR, Park DK, Song M, et al. p75 and neural cell adhesion molecule 1 can identify pathologic Schwann cells in peripheral neuropathies. Ann Clin Transl Neurol [Internet]. 2019;6:1292\u2013301. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.50828","DOI":"10.1002\/acn3.50828"},{"key":"10.1007\/s13311-021-01136-0_bib10","doi-asserted-by":"crossref","unstructured":"Wang H, Davison M, Wang K, Xia T, Kramer M, Call K, et al. Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A. Ann Clin Transl Neurol [Internet]. 2020;7:69\u201382. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.50965","DOI":"10.1002\/acn3.50965"},{"key":"10.1007\/s13311-021-01136-0_bib11","doi-asserted-by":"crossref","unstructured":"Petzold A, Hinds N, Murray NF, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: A potential prognostic marker in Guillain-Barre syndrome. Neurology [Internet]. 2006;67:1071\u20133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17000982","DOI":"10.1212\/01.wnl.0000237334.69665.92"},{"key":"10.1007\/s13311-021-01136-0_bib12","doi-asserted-by":"crossref","unstructured":"Petzold A, Brettschneider J, Jin K, Keir G, Murray NMF, Hirsch NP, et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barr\u00e9 syndrome. Muscle Nerve [Internet]. 2009;40:42\u20139. Available from: http:\/\/doi.wiley.com\/10.1002\/mus.21239","DOI":"10.1002\/mus.21239"},{"key":"10.1007\/s13311-021-01136-0_bib13","doi-asserted-by":"crossref","unstructured":"Wang X-K, Zhang H-L, Meng F-H, Chang M, Wang Y-Z, Jin T, et al. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain\u2013Barr\u00e9 syndrome. Neurol Sci [Internet]. 2013;34:655\u201361. Available from: http:\/\/link.springer.com\/10.1007\/s10072-012-1092-z","DOI":"10.1007\/s10072-012-1092-z"},{"key":"10.1007\/s13311-021-01136-0_bib14","doi-asserted-by":"crossref","unstructured":"Qiao X, Zhang S, Zhao W, Ye H, Yang Y, Zhang Z, et al. Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes. Medicine (Baltimore) [Internet]. 2015;94:e1908. Available from: https:\/\/journals.lww.com\/00005792-201511030-00030","DOI":"10.1097\/MD.0000000000001908"},{"key":"10.1007\/s13311-021-01136-0_bib15","doi-asserted-by":"crossref","unstructured":"Wieske L, Witteveen E, Petzold A, Verhamme C, Schultz MJMJ, van Schaik ININ, et al. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Crit Care [Internet]. 2014 [cited 2014 Feb 21];18:R18. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24443841","DOI":"10.1186\/cc13699"},{"key":"10.1007\/s13311-021-01136-0_bib16","doi-asserted-by":"crossref","unstructured":"Rossor AM, Liu C-H, Petzold A, Malaspina A, Laura M, Greensmith L, et al. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease. Muscle Nerve [Internet]. 2016;53:972\u20135. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25124","DOI":"10.1002\/mus.25124"},{"key":"10.1007\/s13311-021-01136-0_bib17","doi-asserted-by":"crossref","unstructured":"Sun Q, Tang D-D, Yin E-G, Wei L-L, Chen P, Deng S-P, et al. Diagnostic Significance of Serum Levels of Nerve Growth Factor and Brain Derived Neurotrophic Factor in Diabetic Peripheral Neuropathy. Med Sci Monit [Internet]. 2018;24:5943\u201350. Available from: https:\/\/www.medscimonit.com\/abstract\/index\/idArt\/909449","DOI":"10.12659\/MSM.909449"},{"key":"10.1007\/s13311-021-01136-0_bib18","doi-asserted-by":"crossref","unstructured":"Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand [Internet]. 2009;81:402\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.1990.tb00984.x","DOI":"10.1111\/j.1600-0404.1990.tb00984.x"},{"key":"10.1007\/s13311-021-01136-0_bib19","doi-asserted-by":"crossref","unstructured":"Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol [Internet]. 2004;15:1439\u201342. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419460493","DOI":"10.1093\/annonc\/mdh348"},{"key":"10.1007\/s13311-021-01136-0_bib20","doi-asserted-by":"crossref","unstructured":"Youk J, Kim Y-S, Lim J-A, Shin D-Y, Koh Y, Lee S-T, et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. Malik RA, editor. PLoS One [Internet]. 2017;12:e0183491. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0183491","DOI":"10.1371\/journal.pone.0183491"},{"key":"10.1007\/s13311-021-01136-0_bib21","unstructured":"De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res [Internet]. 2000;6:90\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10656436"},{"key":"10.1007\/s13311-021-01136-0_bib22","doi-asserted-by":"crossref","unstructured":"Azoulay D, Lavie D, Horowitz N, Suriu C, Gatt ME, Akria L, et al. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol [Internet]. 2014;164:454\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12624","DOI":"10.1111\/bjh.12624"},{"key":"10.1007\/s13311-021-01136-0_bib23","doi-asserted-by":"crossref","unstructured":"Azoulay D, Giryes S, Nasser R, Sharon R, Horowitz NA. Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism. J Clin Neurol [Internet]. 2019;15:511. Available from: https:\/\/www.thejcn.com\/DOIx.php?id=10.3988\/jcn.2019.15.4.511","DOI":"10.3988\/jcn.2019.15.4.511"},{"key":"10.1007\/s13311-021-01136-0_bib24","doi-asserted-by":"crossref","unstructured":"Kim HC, Cho YJ, Ahn CW, Park KS, Kim JC, Nam JS, et al. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med [Internet]. 2009;26:1228\u201334. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-5491.2009.02856.x","DOI":"10.1111\/j.1464-5491.2009.02856.x"},{"key":"10.1007\/s13311-021-01136-0_bib25","doi-asserted-by":"crossref","unstructured":"Velasco R, Navarro X, Gil-Gil M, Herrando-Grabulosa M, Calls A, Bruna J. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. J Pain Symptom Manage [Internet]. 2017;54:815\u201325. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392417303536","DOI":"10.1016\/j.jpainsymman.2017.04.021"},{"key":"10.1007\/s13311-021-01136-0_bib26","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek A, Mlak R, Bury-Kami\u0144ska M, Mielnik M, Podgajna M, Ku\u015bmierczuk K, et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol [Internet]. 2020;191:77\u201389. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16862","DOI":"10.1111\/bjh.16862"},{"key":"10.1007\/s13311-021-01136-0_bib27","doi-asserted-by":"crossref","unstructured":"Notturno F, Caporale CM, De Lauretis A, Uncini A. Glial fibrillary acidic protein: A marker of axonal Guillain\u2013Barr\u00e8 syndrome and outcome. Muscle Nerve [Internet]. 2008;38:899\u2013903. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.20983","DOI":"10.1002\/mus.20983"},{"key":"10.1007\/s13311-021-01136-0_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.21323","article-title":"Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies","volume":"40","author":"Notturno","year":"2009","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-021-01136-0_bib29","doi-asserted-by":"crossref","unstructured":"Axelsson M, Sj\u00f6gren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barr\u00e9 syndrome: A pilot study. Acta Neurol Scand [Internet]. 2018;138:143\u201350. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12927","DOI":"10.1111\/ane.12927"},{"key":"10.1007\/s13311-021-01136-0_bib30","doi-asserted-by":"crossref","unstructured":"Petzold A, Rosengren L, Verbeek MM, Notturno F, Caporale CM, DeLauretis A, et al. Glial fibrillary acidic protein in Guillain-Barr\u00e9 syndrome: Methodological issues. Muscle Nerve [Internet]. 2009;39:711\u20132. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.21283","DOI":"10.1002\/mus.21283"},{"key":"10.1007\/s13311-021-01136-0_bib31","doi-asserted-by":"crossref","unstructured":"Frithiof R, Rostami E, Kumlien E, Virhammar J, F\u00e4llmar D, Hultstr\u00f6m M, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol [Internet]. International Federation of Clinical Neurophysiology; 2021;132:1733\u201340. Available from: https:\/\/doi.org\/10.1016\/j.clinph.2021.03.016","DOI":"10.1016\/j.clinph.2021.03.016"},{"key":"10.1007\/s13311-021-01136-0_bib32","doi-asserted-by":"crossref","unstructured":"Steiner J, Bernstein H-G, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci [Internet]. 2007;8:2. Available from: https:\/\/bmcneurosci.biomedcentral.com\/articles\/0.1186\/1471-2202-8-2","DOI":"10.1186\/1471-2202-8-2"},{"key":"10.1007\/s13311-021-01136-0_bib33","doi-asserted-by":"crossref","unstructured":"Mokuno K, Kiyosawa K, Sugimura K, Yasuda T, Riku S, Murayama T, et al. Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barr\u00e9 syndrome. Acta Neurol Scand [Internet]. 1994;89:27\u201330. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8178624","DOI":"10.1111\/j.1600-0404.1994.tb01628.x"},{"key":"10.1007\/s13311-021-01136-0_bib34","doi-asserted-by":"crossref","unstructured":"Jander S, Bussini S, Neuen-Jacob E, Bosse F, Menge T, M\u00fcller H-W, et al. Osteopontin: A novel axon-regulated Schwann cell gene. J Neurosci Res [Internet]. 2002;67:156\u201366. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jnr.10099","DOI":"10.1002\/jnr.10099"},{"key":"10.1007\/s13311-021-01136-0_bib35","doi-asserted-by":"crossref","unstructured":"Pizzamiglio C, Ripellino P, Prandi P, Clemente N, Saggia C, Rossi V, et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin [Internet]. 2020;50:47\u201354. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0987705319304241","DOI":"10.1016\/j.neucli.2019.12.001"},{"key":"10.1007\/s13311-021-01136-0_bib36","doi-asserted-by":"crossref","unstructured":"Han R kun, Cheng Y feng, Zhou S shan, Guo H, He R dong, Chi L jun, et al. Increased Circulating Th17 Cell Populations and Elevated CSF Osteopontin and IL-17 Concentrations in Patients with Guillain-Barr\u00e9 Syndrome. J Clin Immunol [Internet]. 2014;34:94\u2013103. Available from: http:\/\/link.springer.com\/10.1007\/s10875-013-9965-3","DOI":"10.1007\/s10875-013-9965-3"},{"key":"10.1007\/s13311-021-01136-0_bib37","doi-asserted-by":"crossref","unstructured":"Day GS, Yarbrough MY, K\u00f6rtvelyessy P, Pr\u00fcss H, Bucelli RC, Fritzler MJ, et al. Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology [Internet]. 2021;96:e2546\u201357. Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000011937","DOI":"10.1212\/WNL.0000000000011937"},{"key":"10.1007\/s13311-021-01136-0_bib38","doi-asserted-by":"crossref","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol [Internet]. Springer US; 2018;14:577\u201389. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30171200","DOI":"10.1038\/s41582-018-0058-z"},{"key":"10.1007\/s13311-021-01136-0_bib39","doi-asserted-by":"crossref","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med [Internet]. 2016;54:1655\u201361. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27071153","DOI":"10.1515\/cclm-2015-1195"},{"key":"10.1007\/s13311-021-01136-0_bib40","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cerme\u00f1o JC, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurol [Internet]. 2019;76:1035. Available from: http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2019.1534"},{"key":"10.1007\/s13311-021-01136-0_bib41","doi-asserted-by":"crossref","unstructured":"Altmann P, Ponleitner M, Rommer PS, Haslacher H, Mucher P, Leutmezer F, et al. Seven day pre-analytical stability of serum and plasma neurofilament light chain. Sci Rep [Internet]. 2021;11:11034. Available from: http:\/\/www.nature.com\/articles\/s41598-021-90639-z","DOI":"10.1038\/s41598-021-90639-z"},{"key":"10.1007\/s13311-021-01136-0_bib42","doi-asserted-by":"crossref","unstructured":"Ashton NJ, Su\u00e1rez-Calvet M, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M, et al. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's Dement Diagnosis, Assess Dis Monit [Internet]. 2021;13:e12168. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34124336","DOI":"10.1002\/dad2.12168"},{"key":"10.1007\/s13311-021-01136-0_bib43","doi-asserted-by":"crossref","unstructured":"Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. Alzheimer's Dement Diagnosis, Assess Dis Monit [Internet]. 2018;10:448\u201351. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1016\/j.dadm.2018.06.001","DOI":"10.1016\/j.dadm.2018.06.001"},{"key":"10.1007\/s13311-021-01136-0_bib44","doi-asserted-by":"crossref","unstructured":"Huesgen KW, Elmelige YO, Yang Z, Chowdhury MAB, Gul S, Maciel CB, et al. Ultra-early serum concentrations of neuronal and astroglial biomarkers predict poor neurological outcome after out-of-hospital cardiac arrest\u2014a pilot neuroprognostic study. Resusc Plus [Internet]. 2021;7:100133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34223394","DOI":"10.1016\/j.resplu.2021.100133"},{"key":"10.1007\/s13311-021-01136-0_bib45","unstructured":"Bar-Or A. Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment. ECTRIMS. 2019."},{"key":"10.1007\/s13311-021-01136-0_bib46","doi-asserted-by":"crossref","unstructured":"Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology [Internet]. 2020;94:e1201\u201312. Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000009097","DOI":"10.1212\/WNL.0000000000009097"},{"key":"10.1007\/s13311-021-01136-0_bib47","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Aguilar L, Camps-Renom P, Lleix\u00e0 C, Pascual-Go\u00f1i E, D\u00edaz-Manera J, Rojas-Garc\u00eda R, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients. J Neurol Neurosurg Psychiatry [Internet]. 2021;92:70\u20137. Available from: https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-323899","DOI":"10.1136\/jnnp-2020-323899"},{"key":"10.1007\/s13311-021-01136-0_bib48","doi-asserted-by":"crossref","unstructured":"Kim S-H, Choi MK, Park NY, Hyun J-W, Lee MY, Kim HJ, et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep [Internet]. Springer US; 2020;10:7995. Available from: http:\/\/dx.doi.org\/10.1038\/s41598-020-64511-5","DOI":"10.1038\/s41598-020-64511-5"},{"key":"10.1007\/s13311-021-01136-0_bib49","doi-asserted-by":"crossref","unstructured":"Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol [Internet]. 2021; Available from: http:\/\/link.springer.com\/10.1007\/s00415-021-10537-2","DOI":"10.1007\/s00415-021-10537-2"},{"key":"10.1007\/s13311-021-01136-0_bib50","doi-asserted-by":"crossref","unstructured":"Hayashi T, Nukui T, Piao J, Sugimoto T, Anada R, Matsuda N, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav [Internet]. 2021;11:187\u201394. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.2084","DOI":"10.1002\/brb3.2084"},{"key":"10.1007\/s13311-021-01136-0_bib51","doi-asserted-by":"crossref","unstructured":"Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, Doorn PA, Michalak Z, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst [Internet]. 2019;24:187\u201394. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30973667","DOI":"10.1111\/jns.12319"},{"key":"10.1007\/s13311-021-01136-0_bib52","doi-asserted-by":"crossref","unstructured":"Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T, et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis [Internet]. 2018;77:1093\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28743789","DOI":"10.1136\/annrheumdis-2017-212045"},{"key":"10.1007\/s13311-021-01136-0_bib53","doi-asserted-by":"crossref","unstructured":"Ticau S, Sridharan G V., Tsour S, Cantley WL, Chan A, Gilbert JA, et al. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology [Internet]. 2021;96:e412\u201322. Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000011090","DOI":"10.1212\/WNL.0000000000011090"},{"key":"10.1007\/s13311-021-01136-0_bib54","doi-asserted-by":"crossref","unstructured":"Abu-Rumeileh S, Parchi P. Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art. Front Neurosci [Internet]. 2021;15:1\u20139. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.648743\/full","DOI":"10.3389\/fnins.2021.648743"},{"key":"10.1007\/s13311-021-01136-0_bib55","doi-asserted-by":"crossref","unstructured":"Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB. A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimers Res Ther [Internet]. Alzheimer's Research & Therapy; 2021;13:101. Available from: https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00841-4","DOI":"10.1186\/s13195-021-00841-4"},{"key":"10.1007\/s13311-021-01136-0_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2021.672954","article-title":"Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain","volume":"15","author":"Gaetani","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1007\/s13311-021-01136-0_bib57","doi-asserted-by":"crossref","unstructured":"Godelaine J, De Schaepdryver M, Bossuyt X, Van Damme P, Claeys KG, Poesen K. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun [Internet]. 2021;3:1\u201310. Available from: https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcab018\/6163280","DOI":"10.1093\/braincomms\/fcab018"},{"key":"10.1007\/s13311-021-01136-0_bib58","doi-asserted-by":"crossref","unstructured":"Morrow JM, Evans MRB, Grider T, Sinclair CDJ, Thedens D, Shah S, et al. Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A. Neurology [Internet]. 2018;91:e1125\u20139. Available from: http:\/\/www.neurology.org\/lookup\/doi\/10.1212\/WNL.0000000000006214","DOI":"10.1212\/WNL.0000000000006214"},{"key":"10.1007\/s13311-021-01136-0_bib59","doi-asserted-by":"crossref","unstructured":"Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology [Internet]. 2015;84:1639\u201343. Available from: http:\/\/www.neurology.org\/cgi\/doi\/10.1212\/WNL.0000000000001491","DOI":"10.1212\/WNL.0000000000001491"},{"key":"10.1007\/s13311-021-01136-0_bib60","doi-asserted-by":"crossref","unstructured":"Park SJ, Kim JK, Kim H-H, Yoon B-A, Ji DY, Lee C-W, et al. Integrative metabolomics reveals unique metabolic traits in Guillain-Barr\u00e9 Syndrome and its variants. Sci Rep [Internet]. 2019;9:1077. Available from: http:\/\/www.nature.com\/articles\/s41598-018-37572-w","DOI":"10.1038\/s41598-018-37572-w"},{"key":"10.1007\/s13311-021-01136-0_bib61","doi-asserted-by":"crossref","unstructured":"Visigalli D, Capodivento G, Basit A, Fern\u00e1ndez R, Hamid Z, Pencov\u00e1 B, et al. Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A. Front Neurol [Internet]. 2020;11. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00903\/full","DOI":"10.3389\/fneur.2020.00903"},{"key":"10.1007\/s13311-021-01136-0_bib62","doi-asserted-by":"crossref","unstructured":"Kramer R, Bielawski J, Kistner-Griffin E, Othman A, Alecu I, Ernst D, et al. Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB J [Internet]. 2015;29:4461\u201372. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1096\/fj.15-272567","DOI":"10.1096\/fj.15-272567"},{"key":"10.1007\/s13311-021-01136-0_bib63","doi-asserted-by":"crossref","unstructured":"Verma P, Devaraj J, Skiles JL, Sajdyk T, Ho RH, Hutchinson R, et al. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy. Sci Rep [Internet]. 2020;10:9659. Available from: http:\/\/www.nature.com\/articles\/s41598-020-66815-y","DOI":"10.1038\/s41598-020-66815-y"},{"key":"10.1007\/s13311-021-01136-0_bib64","doi-asserted-by":"crossref","unstructured":"Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, et al. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat [Internet]. 2018;171:657\u201366. Available from: http:\/\/link.springer.com\/10.1007\/s10549-018-4862-3","DOI":"10.1007\/s10549-018-4862-3"},{"key":"10.1007\/s13311-021-01136-0_bib65","doi-asserted-by":"crossref","unstructured":"Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, et al. Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci [Internet]. 2019;110:3267\u201374. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14178","DOI":"10.1111\/cas.14178"},{"key":"10.1007\/s13311-021-01136-0_bib66","doi-asserted-by":"crossref","unstructured":"Vita GL, Aguennouz M, Polito F, Oteri R, Russo M, Gentile L, et al. Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Front Mol Neurosci [Internet]. 2020;13. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fnmol.2020.00102\/full","DOI":"10.3389\/fnmol.2020.00102"},{"key":"10.1007\/s13311-021-01136-0_bib67","doi-asserted-by":"crossref","unstructured":"Fan B, Chopp M, Zhang ZG, Liu XS. Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy. Front Neurol [Internet]. 2020;11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.558758\/full","DOI":"10.3389\/fneur.2020.558758"},{"key":"10.1007\/s13311-021-01136-0_bib68","doi-asserted-by":"crossref","unstructured":"Peng Q, Mechanic J, Shoieb A, Pardo ID, Schaevitz L, Fenyk-Melody J, et al. Circulating microRNA and automated motion analysis as novel methods of assessing chemotherapy-induced peripheral neuropathy in mice. Borchelt DR, editor. PLoS One [Internet]. 2019;14:e0210995. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0210995","DOI":"10.1371\/journal.pone.0210995"},{"key":"10.1007\/s13311-021-01136-0_bib69","doi-asserted-by":"crossref","unstructured":"Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, et al. Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs. BMJ Support Palliat Care [Internet]. 2020;bmjspcare-2019\u2013001900. Available from: https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/bmjspcare-2019-001900","DOI":"10.1136\/bmjspcare-2019-001900"},{"key":"10.1007\/s13311-021-01136-0_bib70","doi-asserted-by":"crossref","unstructured":"Wang H, Davison M, Wang K, Xia T-H, Call KM, Luo J, et al. MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A. Neurology [Internet]. 2021;97:e489\u2013500. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34031204","DOI":"10.1212\/WNL.0000000000012266"},{"key":"10.1007\/s13311-021-01136-0_bib71","doi-asserted-by":"crossref","unstructured":"Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, et al. International Guillain-Barr\u00e9 Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr\u00e9 syndrome. J Peripher Nerv Syst [Internet]. 2017;22:68\u201376. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jns.12209","DOI":"10.1111\/jns.12209"},{"key":"10.1007\/s13311-021-01136-0_bib72","doi-asserted-by":"crossref","unstructured":"Eftimov F, Bunschoten C, Rajabally Y, Querol L, participants of the 231st ENMC workshop. 231st ENMC International Workshop:: International Standard for CIDP Registry and Biobank, Naarden, The Netherlands, 12\u201314 May 2017. Neuromuscul Disord [Internet]. 2018;28:178\u201384. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29305135","DOI":"10.1016\/j.nmd.2017.10.009"},{"key":"10.1007\/s13311-021-01136-0_bib73","doi-asserted-by":"crossref","unstructured":"Pruppers MHJ, Merkies ISJ, Lunn MPT, Notermans NC, IMAGiNe Study Group. 230th ENMC International Workshop:: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: A consensus collaborative effort, Naarden, The Netherlands, 24\u201326 February 2017. Neuromuscul Disord [Internet]. 2017;27:1065\u201372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896617312087","DOI":"10.1016\/j.nmd.2017.08.001"},{"key":"10.1007\/s13311-021-01136-0_bib74","doi-asserted-by":"crossref","unstructured":"K\u00f6rtvelyessy P, Kuhle J, D\u00fczel E, Vielhaber S, Schmidt C, Heinius A, et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barr\u00e9 Syndrome. Ann Clin Transl Neurol [Internet]. 2020;7:2213\u201320. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.51207","DOI":"10.1002\/acn3.51207"},{"key":"10.1007\/s13311-021-01136-0_bib75","doi-asserted-by":"crossref","unstructured":"Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. Reindl M, editor. PLoS One [Internet]. 2013;8:e75091. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0075091","DOI":"10.1371\/journal.pone.0075091"}],"updated-by":[{"DOI":"10.1007\/s13311-021-01157-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01136-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01136-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:23:34Z","timestamp":1704713014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1878747923007079"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01136-0","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s13311-021-01157-9","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01136-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01157-9","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}